Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Gongwin Biopharm Holdings Co's Median PS Value or its related term are showing as below:
ROCO:6617's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.62 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Gongwin Biopharm Holdings Co (ROCO:6617) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Gongwin Biopharm Holdings Co's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
103.00
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gongwin Biopharm Holdings Co Median PS Value Related Terms
Gongwin Biopharm Holdings Co Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gongwin Biopharm Holdings Co Median PS Value Chart
ROCO:6617 vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Gongwin Biopharm Holdings Co's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gongwin Biopharm Holdings Co Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gongwin Biopharm Holdings Co's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Gongwin Biopharm Holdings Co's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Gongwin Biopharm Holdings Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.296.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gongwin Biopharm Holdings Co (ROCO:6617) has a Median PS Value of NT$0.00 as of Jul. 21, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Gongwin Biopharm Holdings Co and its competitors. According to the industry distribution chart, Gongwin Biopharm Holdings Co ranks #999999 out of 278 companies in the Biotechnology industry.
Is Gongwin Biopharm Holdings Co's Median PS Value too high?
Gongwin Biopharm Holdings Co's current Median PS Value is NT$0.00. Based on the distribution chart, Gongwin Biopharm Holdings Co ranks #999999 out of 278 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gongwin Biopharm Holdings Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gongwin Biopharm Holdings Co's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gongwin Biopharm Holdings Co ranks #999999 out of 278 companies for Median PS Value. This places Gongwin Biopharm Holdings Co in the lower half of its industry. The industry median Median PS Value is 0.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Gongwin Biopharm Holdings Co and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gongwin Biopharm Holdings Co's current Median PS Value is NT$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gongwin Biopharm Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Gongwin Biopharm Holdings Co (ROCO:6617) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$151.75, compared to a current price of NT$103.00 — trading 32.1% below its estimated fair value. The current Median PS Value is NT$0.00. Gongwin Biopharm Holdings Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Gongwin Biopharm Holdings Co (ROCO:6617), the current Median PS Value is NT$0.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gongwin Biopharm Holdings Co (ROCO:6617) Overvalued in 2026?
Based on GuruFocus' analysis, Gongwin Biopharm Holdings Co stock appears to be undervalued.
The current stock price of NT$103.00 is trading 32.1% below its estimated GF Value™ of NT$151.75.
GuruFocus considers Gongwin Biopharm Holdings Co to be Significantly Undervalued.
Key valuation signals for ROCO:6617:
Median PS Value: NT$0.00
GF Value™: NT$151.75 vs. price of NT$103.00 (32.1% below fair value)
No single metric tells the full story. See the ROCO:6617 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gongwin Biopharm Holdings Co Ltd is a Taiwan-based biopharmaceutical company focused on developing novel anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma. The Group includes pharmaceutical research and development, drug testing, pharmaceutical technology consulting, biotechnology services, technology transfer, and the sale of new drugs.
70GF Score
Get the complete analysis for ROCO:6617
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6617 has been successfully added to your 
